Table 2 Comparison of clinical and biological characteristics between acute myeloid leukemia (AML) patients, with or without EKLF and C-MPL expression
From: Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF)
Eklf positive | Eklf negative | P | cMpl positive | cMpl negative | p | |
|---|---|---|---|---|---|---|
Gender of patients (male/female) | 22/13 | 15/15 | 0.297 | 25/21 | 12/7 | 0.514 |
Age/years (median) | 46.0 | 50.6 | 0.463 | 46.2 | 53.8 | 0.237 |
Status Performance/ECOG | 8/13/10/4/0 | 9/5/10/54 | 0.359 | 14/13/13/5/1 | 3/5/7/4/0 | 0.581 |
WBC count,x109/L (median) | 21.05 | 51.15 | 0.049 | 22.4 | 63.7 | 0.006 |
Hemoglobin, g/dL (median) | 9.5 | 9.5 | 0.920 | 9.6 | 9.2 | 0.396 |
Platelet count, x109(median) | 107.0 | 71.1 | 0.114 | 84.3 | 106.1 | 0.388 |
Percentage of Blasts in PB (median) | 38.3 | 47.5 | 0.290 | 37.2 | 53.4 | 0.077 |
M2 vs.non-M2 FAB | 4/30 | 7/23 | 0.221 | 7/39 | 4/14 | 0.504 |
M3 vs.non-M3 FAB | 7/28 | 2/26 | 0.147 | 8/37 | 1/17 | 0.210 |
M5 vs.non-M5 FAB | 4/30 | 8/22 | 0.127 | 10/36 | 2/16 | 0.327 |
WHO Type | 9/10/3/12 | 11/12/1/20 | 0.140 | 11/12/1/20 | 3/4/2/9 | 0.451 |
Primary/Secondary LMA | 24/11 | 27/3 | 0.036 | 37/9 | 14/5 | 0.547 |
Cytogenetic (MRC) | 10/16/6 | 5/15/6 | 0.580 | 11/22/9 | 4/9/3 | 0.961 |
Cr 7 Alterations (yes/no) | 5/27 | 2/25 | 0.331 | 4/39 | 3/13 | 0.318 |
Cr 5 Alterations (yes/no) | 2/30 | 5/22 | 0.147 | 5/38 | 2/14 | 0.927 |
Cr 11 Alterations (yes/no) | 6/26 | 5/22 | 0.982 | 7/36 | 4/12 | 0.444 |
CD34 Blasts (yes/no) | 19/16 | 14/15 | 0.632 | 24/21 | 9/10 | 0.663 |
CD117 Blasts (yes/no) | 22/13 | 19/10 | 0.825 | 29/16 | 12/7 | 0.922 |
CD15 Blats (yes/no) | 12/19 | 19/9 | 0.025 | 19/22 | 12/6 | 0.150 |
CD11B Blasts (yes/no) | 5/25 | 13/14 | 0.011 | 13/28 | 5/11 | 0.973 |
CD11C BLasts (yes/no) | 5/0 | 10/4 | 0.179 | 10/2 | 5/2 | 0.539 |
CD133 BLasts (yes/no) | 10/18 | 10/9 | 0.250 | 16/19 | 4/8 | 0.454 |
CD123 Blasts (yes/no) | 5/16 | 7/7 | 0.110 | 6/18 | 6/5 | 0.087 |
HLA DR + BLasts (yes/no) | 19/9 | 15/12 | 0.348 | 26/14 | 8/7 | 0.428 |
CD56 Blasts (yes/no) | 6/29 | 5/25 | 0.959 | 7/39 | 4/15 | 0.568 |
T-cell markers Blasts (yes/no) | 5/11 | 4/20 | 0.279 | 3/23 | 6/8 | 0.024 |
Erythroblasts BM | 2/6/11 | 0/14/10 | 0.057` | 1/12/17 | 1/8/4/3 | 0.460 |
Gata-1 Expression (yes/no) | 24/11 | 11/19 | 0.010 | 26/20 | 9/10 | 0.501 |
Gata-2 Expression (yes/no) | 27/8 | 13/17 | 0.005 | 31/15 | 9/10 | 0.131 |
EKLF Expression (yes/no) | 28/18 | 7/12 | 0.077 | |||
cMPL Expression (yes/no) | 28/7 | 18/12 | 0.007 | |||
Gat-1 (Median Expression)* | 7.28 | 0.12 | 0.038 | 5.56 | 0.12 | 0.761 |
Gat-2 (Median Expression)* | 1178.01 | 466.75 | 0.096 | 1009.84 | 462.12 | 0.552 |
EKLF (Median Expression)* | 19.54 | 113.68 | 0.096 | |||
cMPL(Median Expression)* | 10.9 | 9.4 | 0.174 | |||
Mutated NPM1 (yes/no) | 3/20 | 6/15 | 0.202 | 4/25 | 5/10 | 0.128 |
Mutated FLT3 (yes/no) | 4/19 | 5/16 | 0.598 | 4/25 | 5/10 | 0.128 |